Advances in antibody phage display technology.

Antibody discovery Antigen presentation Library design Phage display Selection strategy

Journal

Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391

Informations de publication

Date de publication:
08 2022
Historique:
received: 14 01 2022
revised: 24 03 2022
accepted: 04 05 2022
pubmed: 14 5 2022
medline: 22 6 2022
entrez: 13 5 2022
Statut: ppublish

Résumé

Phage display technology can be used for the discovery of antibodies for research, diagnostic, and therapeutic purposes. In this review, we present and discuss key parameters that can be optimized when performing phage display selection campaigns, including the use of different antibody formats and advanced strategies for antigen presentation, such as immobilization, liposomes, nanodiscs, virus-like particles, and whole cells. Furthermore, we provide insights into selection strategies that can be used for the discovery of antibodies with complex binding requirements, such as targeting a specific epitope, cross-reactivity, or pH-dependent binding. Lastly, we provide a description of specialized phage display libraries for the discovery of bispecific antibodies and pH-sensitive antibodies. Together, these methods can be used to improve antibody discovery campaigns against all types of antigens.

Identifiants

pubmed: 35550436
pii: S1359-6446(22)00173-8
doi: 10.1016/j.drudis.2022.05.002
pii:
doi:

Substances chimiques

Antibodies 0
Epitopes 0
Peptide Library 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2151-2169

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Line Ledsgaard (L)

Department of Biotechnology and Biomedicine, Technical University of Denmark, DK-2800 Kongens Lyngby, Denmark. Electronic address: liljen@dtu.dk.

Anne Ljungars (A)

Department of Biotechnology and Biomedicine, Technical University of Denmark, DK-2800 Kongens Lyngby, Denmark.

Charlotte Rimbault (C)

Department of Biotechnology and Biomedicine, Technical University of Denmark, DK-2800 Kongens Lyngby, Denmark.

Christoffer V Sørensen (CV)

Department of Biotechnology and Biomedicine, Technical University of Denmark, DK-2800 Kongens Lyngby, Denmark.

Tulika Tulika (T)

Department of Biotechnology and Biomedicine, Technical University of Denmark, DK-2800 Kongens Lyngby, Denmark.

Jack Wade (J)

Department of Biotechnology and Biomedicine, Technical University of Denmark, DK-2800 Kongens Lyngby, Denmark.

Yessica Wouters (Y)

Department of Biotechnology and Biomedicine, Technical University of Denmark, DK-2800 Kongens Lyngby, Denmark.

John McCafferty (J)

Department of Medicine, Addenbrookes Hospital, Box 157, Hills Road, Cambridge CB2 0QQ, UK; Department of Medicine, Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK.

Andreas H Laustsen (AH)

Department of Biotechnology and Biomedicine, Technical University of Denmark, DK-2800 Kongens Lyngby, Denmark. Electronic address: ahola@bio.dtu.dk.

Articles similaires

Genome, Viral Ralstonia Composting Solanum lycopersicum Bacteriophages
1.00
Immunoconjugates Humans Antibodies, Bispecific Receptor, ErbB-2 Cell Line, Tumor
Host Specificity Bacteriophages Genomics Algorithms Escherichia coli
Editorial Policies Humans Ethics, Research Technology

Classifications MeSH